BioCentury | Oct 25, 2004
Company News

Kinexis, Merck deal

...small molecules against a prokineticin receptor target from Kinexis, for use in developing CNS therapeutics. Kinexis...
...for use in developing CNS therapeutics. Kinexis is eligible for additional milestones plus potential royalties. Kinexis Inc....
BioCentury | Mar 15, 2004
Strategy

Fitting in with Merck

...schizophrenia Neurogen deal Preclin Compounds targeting vanilloid receptor 1 (VR1) -- pain, urinary incontinence Kinexis...
BioCentury | Jul 28, 2003
Company News

Kinexis, Merck deal

...developing CNS therapeutics. Kinexis will receive research funding and is eligible for milestones and royalties. Kinexis Inc....
BioCentury | Jul 21, 2003
Company News

Kinexis, Merck neurological deal

...against a prokineticin receptor target from Kinexis (Carlsbad, Calif.), for use in developing CNS therapeutics. Kinexis...
Items per page:
1 - 4 of 4
BioCentury | Oct 25, 2004
Company News

Kinexis, Merck deal

...small molecules against a prokineticin receptor target from Kinexis, for use in developing CNS therapeutics. Kinexis...
...for use in developing CNS therapeutics. Kinexis is eligible for additional milestones plus potential royalties. Kinexis Inc....
BioCentury | Mar 15, 2004
Strategy

Fitting in with Merck

...schizophrenia Neurogen deal Preclin Compounds targeting vanilloid receptor 1 (VR1) -- pain, urinary incontinence Kinexis...
BioCentury | Jul 28, 2003
Company News

Kinexis, Merck deal

...developing CNS therapeutics. Kinexis will receive research funding and is eligible for milestones and royalties. Kinexis Inc....
BioCentury | Jul 21, 2003
Company News

Kinexis, Merck neurological deal

...against a prokineticin receptor target from Kinexis (Carlsbad, Calif.), for use in developing CNS therapeutics. Kinexis...
Items per page:
1 - 4 of 4